anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an apparatus for controlling body condition which can prevent impersonation of an examinee.  <P>SOLUTION: A storing part 5 memorizes personal information on the examinee who undergoes examination of his or her body condition. The body information identifying device 30 identifies the examinee based on the iris data of the examinee and sends the identifying information on a person in question. The body condition examining device 20 examines the alcohol intake of the examinee and obtains the examination data. In the apparatus 1 for controlling the body condition, an input and output means 2 is connected to the body information identifying device 30 and the body condition examining device 20. The directing means 3a to start the examination receives the identifying information on the person in question from the body information identifying device 30 and sends the direction to start the examination to the body condition examining device 20. The body condition examining means 3b receives the examination data of the examinee from the body condition examining device and the personal information contained in the identification information on the person in question from the directing means 3a to start examination 3a, and stores the examination data in the storing part 5 making a connection with the corresponding personal information.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery devices. The bioadhesive properties of a polymer are enhanced by incorporating a anhydrideoligome into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Anhydrideoligomes which enhance the bioadhesive properties of a polymer include water-insoluble anhydrideoligomes such as water-insoluble metal oxides, including oxides of calcium, iron, copper and zinc. The anhydrideoligomes can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, metal oxides can be incorporated within polymers used to form or coat drug delivery devices, such as microspheres, which contain a drug or diagnostic agent. The metal oxides can be provided in the form of a fine dispersion of particles on the surface of a polymer that coats or forms the devices, which enhances the ability of the devices to bind to mucosal membranes. The polymers, for example in the form of microspheres, have improved ability to adhere to mucosal membranes, and thus can be used to deliver a drug or diagnostic agent via any of a range of mucosal membrane surfaces including-those of the gastrointestinal, respiratory, excretory and reproductive tracts.
PURPOSE:A bathing agent having high bathing effects, being rapidly ad completely dissolved in warm water in a bathtub when added to it, causing no bathing scum, etc., obtained by adding a hot spring component, a humectant, etc., to a water-soluble sheet bag comprising pullulan, etc. CONSTITUTION:A water-soluble sheet bag comprising pullulan or pullulan and polyvinyl alcohol and/or polyvinyl pyrrolidone is packed with at least one component selected from a hot spring component, humectant, bath oil, essence extracted from crude drug, perfume and colorant optionally by adding the component to part of the sheet. The amount of polyvinyl alcohol and polyvinyl pyrrolidone is <=50pts.wt. based on 100pts.wt. pullulan. EFFECT:Having skin wetting action, stabilizing action preservation of other component, preventing action of removal of perfume, capable of dispersing sufficiently fragrance during dissolution and preventing bad impression of too strong fragrance before dissolution caused by conventional bathing agent.
The DPR group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice. At the time of silo placement for staged procedure, the JP drain will be sterilely placed intra-abdominally through the top of the silo. Subjects will be treated with adjuvant direct peritoneal resuscitation (DPR) and subsequently serially reduced in silo until the abdomen is closed (during the entirety of silo placement), which is usually four to five days.
NEW MATERIAL:A compound AIL-B of formula I (R is H or acyl). USE:An antibiotic substance having antimicrobial and antitumor activity. PREPARATION:A microorganism, belonging to the genus Streptomyces, and capable of producing AIL-B, particularly Y-32026 strain (FERM-P No.6313) is cultivated in a fermenter by the aerated spinner culture method, preferably at 27-30 deg.C and 6-8pH to stop the cultivation when the production reaches the maximum. The culture fluid is then filtered and separated into wet microbial cells and culture filtrate. Both are then extracted respectively to give extracted solutions, which are together or separately concentrated. The concentration residue is then adsorbed on a silica gel column, and eluted with a suitable solvent, e.g. chloroform-methanol based solvent, while increasing slowly the polarity thereof with varied mixing ratio. The aimed AIL-B is obtained as a fraction eluting just after the elution of AIL.
The intramuscular dosage will vary with the condition being treated. When employed as a temporary substitute for oral therapy, a single injection during each 24 hour period of a dose of the suspension equal to the total daily oral dose of methylprednisolone tablets USP is usually sufficient. When a prolonged effect is desired, the weekly dose may be calculated by multiplying the daily oral dose by 7 and given as a single intramuscular injection. 

In pediatric patients, the initial dose of methylprednisolone may vary depending on the specific disease entity being treated. Dosage must be individualized according to the severity of the disease and response of the patient. The recommended dosage may be reduced for pediatric patients, but dosage should be governed by the severity of the condition rather than by strict adherence to the ratio indicated by age or body weight. 

In patients with the adrenogenital syndrome, a single intramuscular injection of 40 mg every two weeks may be adequate. For maintenance of patients with rheumatoid arthritis, the weekly intramuscular dose will vary from 40 to 120 mg. The usual dosage for patients with dermatologic lesions benefited by systemic corticoid therapy is 40 to 120 mg of methylprednisolone acetate administered intramuscularly at weekly intervals for one to four weeks. In acute severe dermatitis due to poison ivy, relief may result within 8 to 12 hours following intramuscular administration of a single dose of 80 to 120 mg. In chronic contact dermatitis, repeated injections at 5 to 10 day intervals may be necessary. In seborrheic dermatitis, a weekly dose of 80 mg may be adequate to control the condition. 

Following intramuscular administration of 80 to 120 mg to asthmatic patients, relief may result within 6 to 48 hours and persist for several days to two weeks. Similarly in patients with allergic rhinitis (hay fever), an intramuscular dose of 80 to 120 mg may be followed by relief of coryzal symptoms within six hours persisting for several days to three weeks. 

If signs of stress are associated with the condition being treated, the dosage of the suspension should be increased. If a rapid hormonal effect of maximum intensity is required, the intravenous administration of highly soluble methylprednisolone sodium succinate is indicated. 

In treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of methylprednisolone for a week followed by 64 mg every other day for 1 month have been shown to be effective. 

For the purpose of comparison, the following is the equivalent milligram dose of the various glucocorticoids:

These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.
An acrylic radiopaque bone cement for orthopedic use comprises a solid phase composed of a mixture of at least one poly(methyl acrylate)-based polymer, one free-radical polymerization initiator and one or more substances opaque to X-rays, and a liquid phase substantially composed of a mixture of at least one monomer, one accelerator and one stabilizer. The radiopaque substances comprise metallic tungsten and tantalum particles, compounds or mixtures thereof, covered with a polymer coating compatible with said bone cement. The coating layer of the particles of radiopaque substances is an acrylic polymer based on poly(methyl methacrylate). The amount of radiopacifying element is between 1% and 20% by weight, relative to the solid phase, preferably between 2% and 5% by weight, relative to the solid phase. The solid phase may additionally comprise one or more pharmacologically active substances. The method for its preparation consists in preparing the radiopacifying material by coating the metal particles with a layer of a polymer which is compatible with the matrix and exhibits oxygen barrier properties such that said layer does not dissolve completely in the liquid phase so as to keep its oxygen barrier properties at least partly unchanged.
TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
Cases of overdosage with XENPOZYME have been reported in pediatric patients during dose escalation. Some patients experienced serious adverse reactions including death within 24 hours of initial dose [see Warnings and Precautions (5.2)]. The clinical findings included fever, hypotension, gastrointestinal bleeding, marked elevation in liver tests, metabolic acidosis, respiratory failure, and vomiting.

There is no known specific antidote for XENPOZYME overdosage. In the event of overdosage, immediately stop the infusion, and monitor the patient closely in a hospital setting for the development of hypersensitivity reactions and IARs including acute phase reactions. For the management of adverse reactions, see Warnings and Precautions (5.1, 5.2, 5.3) and Adverse Reactions (6.1).
Glucagon-like peptide 1 (GLP-1) analogues have been commercialized for the management of type 2 diabetes. Recent studies have underscored GLP-1's role as a modulator of alcohol-related behavior. However, the role of the GLP-1 analogue liraglutide on alcohol-withdrawal responses have not been fully elucidated. Liraglutide binds to the G-protein-coupled receptor and activates an adenylyl cyclase and the associated classic growth factor signaling pathway, which acts growth factor-like and neuroprotective properties. The underlying neurobiological mechanisms of liraglutide on alcohol withdrawal remains unknown. This study endeavored to explore the effects of liraglutide on the emotion and memory ability of alcohol-withdrawal mice, and synaptic morphology in the medial prefrontal cortex (mPFC) and the hippocampus (HP), and thus affects the relapse-like drinking of alcohol-withdrawal mice. The alcohol-withdrawal group was reintroduced to a 20% v/v alcohol and water through the two-bottle choice for four consecutive days, a period referred to as alcohol re-drinking. Male C57BL/6J mice were exposed to a regimen of 20% alcohol and water for a duration of 6 weeks. This regimen established the two-bottle choice model of alcohol exposure. Learning capabilities, memory proficiency, and anxiety-like behavior were evaluated using the Morris water maze, open field, and elevated plus maze paradigms. Furthermore, synaptic morphology and the levels of synaptic transport-related proteins were assessed via Golgi staining and Western Blot analysis after a two-week alcohol deprivation period. Alcohol re-drinking of alcohol-withdrawal mice was also evaluated using a two-bottle choice paradigm. Our findings indicate that liraglutide can substantially decrease alcohol consumption and preference (p < 0.05) in the alcohol group and enhance learning and memory performance (p < 0.01), as well as alleviate anxiety-like behavior (p < 0.01) of alcohol-withdrawal mice. Alcohol consumption led to a reduction in dendritic spine density in the mPFC and HP, which was restored to normal levels by liraglutide (p < 0.001). Furthermore, liraglutide was found to augment the levels of synaptic transport-related proteins in mice subjected to alcohol withdrawal (p < 0.01). The study findings corroborate that liraglutide has the potential to mitigate alcohol consumption and ameliorate the memory impairments and anxiety induced by alcohol withdrawal. The therapeutic efficacy of liraglutide might be attributed to its role in counteracting synapse loss in the mPFC and HP regions and thus prevented relapse-like drinking in alcohol-withdrawal mice.
FIELD: molecular biology; cellular biology; medicine; pharmacology.SUBSTANCE: invention relates to the field of molecular and cellular biology, medicine and pharmacology, in particular to a drug for the treatment of tissue fibrosis, a method for its preparation and a method for the treatment of fibrosis caused by tissue damage using the specified drug. The drug contains a fraction of extracellular vesicles in the secretome of mesenchymal stromal cells (hereinafter – MSC) or an isolated fraction of extracellular vesicles isolated from the secretome of MSC having surface markers HSP70, CD9, CD81 and CD63, as well as a diameter size from 20 to 420 nm, in the amount of 1-3*10^10 particles per ml. Extracellular vesicles carry special microRNA in their composition. To implement the method for obtaining the specified drug, human MSC are first cultured to 90% of confluent or monolayer in a medium that supports the growth of undifferentiated human mesenchymal cells. Then, cells are washed with a buffer solution, and MSC are conditioned in a serum-free and animal-free growth medium that supports cell viability of at least 70% and that is suitable for therapeutic use, for 2-7 days. After that, the cultivation medium containing secretion products of human MSC is selected, cell residues are removed from it, and it is purified from low-molecular components, followed by concentration using ultrafiltration. Next, the specified medium is evaluated for the content of the fraction of extracellular vesicles with surface markers, the size and number of particles per ml are determined, as well as the presence of the specified microRNA in their composition is evaluated. At the same time, 10 kDa filters are used to obtain a fraction of extracellular vesicles in human MSC secretome, and 1000 kDa filters are used to obtain an isolated fraction of extracellular vesicles isolated from MSC secretome, with an acceptable error value of no more than 5%.EFFECT: present invention makes it possible to expand the arsenal of means that effectively suppress tissue fibrosis or prevent the development of tissue fibrosis.28 cl, 16 dwg, 4 tbl, 10 ex
The active ingredient in edaravone injection is edaravone, which is a member of the substituted 2-pyrazolin-5one class. The chemical name of edaravone is [3-methyl-1-phenyl-2-pyrazolin-5-one]. The molecular formula is C10H10N2O and the molecular weight is 174.20. 

The chemical structure is: 

Edaravone is a white crystalline powder with a melting point of 129.7°C. It is freely soluble in acetic acid, methanol, or ethanol and slightly soluble in water or diethyl ether. 

Edaravone injection is a clear, colorless liquid provided as a sterile solution. 

Edaravone injection is supplied for intravenous infusion in a polypropylene bag containing 30 mg edaravone in 100 mL isotonic, sterile, aqueous solution, which is further overwrapped with silicon oxide-coated polyester film secondary packaging. The overwrapped package also contains an oxygen absorber and oxygen indicator to minimize oxidation. Each bag contains the following inactive ingredients: L-cysteine hydrochloride hydrate (10 mg), sodium bisulfite (20 mg). Sodium chloride is added for isotonicity and phosphoric acid and sodium hydroxide are added to adjust to pH 4.
Impaired Liver Function  


Do not use Tri-VyLibra Lo in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Tri-VyLibra Lo if jaundice develops.

Liver Tumors  


Tri-VyLibra Lo is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
PURPOSE:To obtain a perfumery-containing composition applicable to oral cavity without causing unagreeable, astringent or bitter taste to the palate, having improved retainability of perfumery, and suitable especially for oral cavity application, by adding a 16-28C higher aliphatic alcohol which is liquid at normal temperature, as a perfumery retainer. CONSTITUTION:A perfumery-containing composition containing perfumery such as l-menthol, peppermint oil, etc. is compounded with a perfumery retainer comprising a liquid 16-28C higher aliphatic alcohol having branched structure and/or unsaturated bond, e.g. magnolia alcohol. The weight ratio of the perfumery retainer:perfumery is 1:9-7:3, especially 3:7-6:4. The retainability of perfumery can be improved, the effect of perfumery can be maintained for a long period and since the alcohol is tasteless and odorless and resistant to hydrolysis, a composition suitable as an agent for oral cavity application can be prepared. The above alcohol exhibits high foam-stabilizing effect in a system containing a surfactant.
It seems to be important to examine peripheral changes in the pathogenesis of SMA. Although it shows that the target center in SMA is alpha motor neurons located in the anterior horn of the spinal cord, considering the interaction network of interneurons, cerebellum, neuromuscular junction, gamma-alpha motor neuron pool, descending and ascending pathways, and reflex arc, it has potential to be investigated in individuals with SMA. This suggests that it may have important consequences for peripheral mechanisms. It may be important to examine muscle mechanical properties to reveal any potential correlations between SMA types and disease progression. In addition, moyotonometer results can be a key evaluation method in examining treatment efficacy, diagnosis and disease course. However, in order for these activities to be observed with myotonometer, first of all, the reliability of its use in individuals with SMA should be questioned.
Somatization disorder is a syndrome characterized by the presence of multiple medically unexplained physical symptoms. It often results in substantial functional impairment and the need for extensive medical treatment. Neither pharmacological nor psychosocial treatments for the disease have demonstrated clinical success. People with somatization disorder may benefit from a treatment that integrates emotion-centered strategies into cognitive behavioral therapy. The long-term effectiveness of this treatment has not been established, however. This study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder.

Participants in this open-label study will be randomly assigned to receive either cognitive-affective behavior therapy (CABT) or standard medical care that is augmented by a psychiatric consultation. Treatment will last 4 months. Assessments of somatic symptomatology, functional impairment, and health care costs will occur at screening, baseline (1 to 2 weeks after screening), and 4, 10, and 16 months after baseline. The visits at 10 and 16 months post-baseline will assess specifically the long-term efficacy of the treatment.
A solution of 10 g fructose in 200 mL of tap water will be infused once over a period of 20min. during 1 of the 3 investigation days.
PURPOSE: Shock Index is used to predict injury severity and adverse outcomes in trauma patients, but pediatric age-adjusted shock index (SIPA) has superior performance in pediatric patients older than 1 year. Pediatric age-adjusted shock index scores younger than 1 year have not been well studied. This project aimed to establish and evaluate SIPA cut point data points for patients younger than 1 year.
METHODS: Using age-based vital signs, we developed cut point values for patients younger than 1 year using our institutional trauma data. All trauma patients younger than 12 months were included, and clinical outcomes were recorded. Pediatric age-adjusted shock index cut points were defined using age-specific vital sign limits (SIPA-VS) and tested against optimal cut points defined by receiver operating characteristic analysis (SIPA-ROC) and a cut point of 1.2 (SIPA-Nordin), which is used for patients aged 1 to 4 years. Student's t test, χ 2 tests, analysis of variance, and test characteristics were used to analyze groups.
RESULTS: A total of 609 pediatric trauma patients younger than 12 months were identified from 2018 to 2022. Pediatric age-adjusted shock index scores were calculated for 483 patients. There were 406 patients with blunt trauma and 17 with penetrating. SIPA-Nordin was elevated in 81.6% (n = 397) of patients, compared with SIPA-VS 21% (n = 101) and SIPA-ROC 31% (n = 150). In comparison with SIPA-Nordin, both SIPA-VS and SIPA-ROC score exhibited superior specificity and negative predictive values for multiple outcomes. Elevated SIPA-ROC scores had statistically significant associations with intensive care unit admission, mechanical ventilation, severe anemia, transfusion during hospital admission, and in-hospital mortality.
CONCLUSION: Pediatric age-adjusted shock index is a useful tool in identifying patients at risk for several complications of severe traumatic injury. Pediatric age-adjusted shock index cut points had high negative predictive value and specificity for many outcomes. This study proposes cut point values that may aid in clinical decision making for trauma patients younger than 1 year.
LEVEL OF EVIDENCE: Diagnostic Test/Criteria; Level IV.